AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04560699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical care
Description: medical care three times during the study period; baseline, week 13 and week 26
Study NCT01630876 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vitrectomy only group
Description: The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
Study NCT01630876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined therapy group
Description: The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
Study NCT03755349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of burr-hole covers
Description: Placement of a burr-hole cover (Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520) fixed with 2 screws (Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934) on each of two burr-holes
Study NCT03755349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No placement of burr-hole covers
Description: In the control group, none of the burr-holes is covered, representing our current standard of care. In patients with bilateral cSDH, none of the burr-holes on the control side are covered with burr-hole covers.
Study NCT01967329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Triple
Description: Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
Study NCT01967329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential
Description: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
Study NCT01967329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple
Description: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
Study NCT01976091 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SRP-9004
Description: Isolated Limb Infusion (ILI)
Study NCT03042819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
Study NCT03042819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
Study NCT03967444 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hyaluronic acid
Description: Injectable gel for lip augmentation
Study NCT03967444 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hyaluronic acid
Description: Injectable gel. Lip Augmentation and other wrinkles/folds
Study NCT02359097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo MRI including DSC or DCE-CBV mapping
Study NCT02359097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV
Study NCT02359097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Description: Given IV
Study NCT02359097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI including SS-CBV
Study NCT01605799 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IOK Killing Treatment
Description: The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
Study NCT01605799 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: IOK Killing Treatment
Description: The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
Study NCT01605799 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait list control group
Description: Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
Study NCT04129996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab in combination with nab-paclitaxel and famitinib
Description: camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer
Study NCT06369727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOB015B
Description: Topcal formulation
Study NCT06369727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MOB015B vehicle
Description: Topcal formulation
Study NCT06369727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Negative irritant solution of 0.9% saline
Description: Negative control
Study NCT01902095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tooth powder
Description: Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.
Study NCT01902095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth paste (control)
Description: Active Comparator
Study NCT01641185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation with protons or carbon ions
Study NCT03811704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgical navigation system
Description: We will use this navigation system to guide de liver resection.
Study NCT03811704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: ICG was administered 24 hours before the operation or intravenously after clamping the Glissonian sheaths flowing in the cancer-bearing hepatic segment, or directly into the portal branches supplying blood flow to the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
Study NCT00558649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine (FLUARIX®)
Description: Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
Study NCT00558649 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flu Vaccine (FLUARIX®)
Description: Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
Study NCT00179192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty
Description: angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist
Study NCT00179192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure
Study NCT03527732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albendazole
Description: Monotherapy of albendazole (400 mg)
Study NCT03527732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole and Ivermectin
Description: Combination therapy of albendazole (400 mg) and ivermectin (200 µg/kg)
Study NCT03032978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Pulp capping material
Study NCT03032978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium silicate
Description: Pulp capping material
Study NCT03599089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: single-dose wound infiltration prior to surgical incision closure
Study NCT03599089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose wound infiltration prior to surgical incision closure
Study NCT03599089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 30mg IV administered intraoperatively
Study NCT03599089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: 30mg IV administered intraoperatively
Study NCT03599089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg IV administered intraoperatively
Study NCT03599089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg IV administered intraoperatively
Study NCT03599089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5mg PO prn post-surgery
Study NCT03599089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 5mg PO prn post-surgery
Study NCT03599089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.5% infiltration pre-surgery
Study NCT03599089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.5% infiltration pre-surgery
Study NCT00624182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine for URLC10
Description: Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
Study NCT00624182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
Study NCT01885130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Daily Advance Ultra Hydrating Lotion
Description: 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
Study NCT02903329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Detoxification
Description: Two ways of composing the detoxification protocol
Study NCT02283827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study NCT02283827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Study NCT02193503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells
Study NCT03941288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued.
Study NCT03941288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued.
Study NCT00399906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-582949
Description: Tablets, Oral, Once daily, 12 weeks
Study NCT03294031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Warm-up exercises included Abdominal and costal breathing and Pelvic Clock. Some exercises included in the main part of the mat session were Arm arcs, Curls up, Femur arcs, Shoulder bridge, Leg circles, among others. The main part of the sitting/standing session included in standing position exercises like Standing on one leg with support, Neck rolls, Side leg lift with support and in sitting position Spine stretch 5, Elbows back with hands behind his head, Heel/knee slides, Shoulder drops, Knee folds, among others. In mat sessions, cooling exercises included in standing position Hamstring stretch and Abdominal Breathing and Rest position and in sitting/standing session Stretching and Abdominal Breathing.
Study NCT03294031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise
Description: All sessions started with a 15-minute warm-up phase based on walking performance and joint mobility exercises. It was followed by a 35-minute second phase, which included low-impact aerobics (music tempo was set at 120 beats per minute), gross motor coordination tasks and balance activities. The final 5-minute phase focused on gentle stretching exercises.
Study NCT03312959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperbaric bupvacaine in Peribulbar block
Description: hyperbaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
Study NCT03312959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isobaric bupvacaine in Peribulbar block
Description: isobaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
Study NCT00805480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 was administered intravenously.
Study NCT00805480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to AIN457 was administered intravenously.
Study NCT00805480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AIN457 was administered intravenously.
Study NCT01007578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon catheter angioplasty
Description: Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
Study NCT04793178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Reserve Index, Masimo Corporation, USA.
Description: The oxygen reserve index (ORI) is a new feature of multiple wavelength pulse oximetry that provides real-time visibility to oxygenation status in the moderate hyperoxic range (PaO2 of approximately 100-200 mm Hg).
Study NCT04793178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index, Masimo Corporation, USA.
Description: The oxygen reserve index (ORI) is a new feature of multiple wavelength pulse oximetry that provides real-time visibility to oxygenation status in the moderate hyperoxic range (PaO2 of approximately 100-200 mm Hg).
Study NCT01327157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal adjustment.
Description: It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this to start. Will be held palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After starts the adjustment following the rules of Guichet with a cylindrical drill with a thin cut . basic principles 1 Occlusive stress maximum distribution in centric relation 2 The occlusive strengths should by the teeth's major axis.3 When the contact is surface to surface, it must be exchanged to another surface point. 4 Once the stability to the centric relation is achieved, it should be kept. The rules to guide the occlusal adjustment selective grinding .
Study NCT01327157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual analog scale.
Description: Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.
Study NCT01327157 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Visual analog scale.
Description: Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.
Study NCT02201407 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
Study NCT04538027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Microdiscectomy at 6 weeks of symptoms
Description: Microscope assisted lumbar discectomy done at 6 weeks of starting symptoms
Study NCT04538027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Microdiscectomy at 3 months of symptoms
Description: Microscope assisted lumbar discectomy done at 3 months of starting symptoms
Study NCT04538027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Microdiscectomy at 6 months of symptoms
Description: Microscope assisted lumbar discectomy done at 6 months of starting symptoms
Study NCT02295527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based physical exercise intervention
Description: Progressive strengthening of muscle groups ankle dorsi flexors, knee extensors and hip abductors and progressive balance training according to individual capacity:weight-bearing, limits of stability, change of position/direction, maintenance of static and dynamic stability, anticipatory adjustments using different bases of support and different sensory conditions. Dynamic exercises involving spin on its own axis, sitting and standing, up and down stairs, functional reach, steps in different directions and walk training. In the first session the physiotherapist will choose two exercises that best address the participant function goals and will add more exercises each week according to the level of participants' ability and motivation. Participants will receive a detailed booklet, containing photos and instructions of the12 exercises.Visits to follow up exercises will be conducted by the physiotherapists to progress the exercises.
Study NCT02295527 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group Usual Care
Description: This group will receive usual care and will not have any disadvantage in participating in the study. We understand that usual care is what participant receives based on the network of health care in which he/she is inserted. The participants will receive at baseline assessment a diary falls logbook and a guidance booklet containing information about prevention of falls, fractures and bone health that will be explained at the moment.
Study NCT03156088 — intervention group
Intervention type: DEVICE
Intervention: Sacral Neuromodulator InterStim
Study NCT00399906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, Once daily, 12 weeks
Study NCT01254422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
Description: 0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
Study NCT01254422 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl 0.9%
Description: 0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
Study NCT01036048 — intervention group
Intervention type: DEVICE
Intervention: drug eluting stent
Description: pts with cabg disease treated with drug eluting stent